Verona Pharma Plc
(London Stock Exchange, The : VNAPF)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MDCOThe Medicines Co.
0.37%84.2120.1%$585.94m
AMRNAmarin Corp. Plc
2.93%22.451.7%$318.11m
VRXValeant Pharmaceuticals International, Inc.
0.52%29.1014.1%$171.23m
BHCBausch Health Cos., Inc.
0.52%29.100.0%$100.43m
JAZZJazz Pharmaceuticals Plc
0.92%149.462.3%$94.15m
SAGESAGE Therapeutics, Inc.
7.11%64.468.6%$93.27m
GWPHGW Pharmaceuticals Plc
-2.39%101.056.2%$88.36m
ICPTIntercept Pharmaceuticals, Inc.
-10.27%107.4816.9%$82.62m
PRGOPerrigo Co. Plc
0.97%52.316.8%$66.45m
AXSMAxsome Therapeutics, Inc.
5.07%45.432.0%$55.58m
HZNPHorizon Therapeutics Plc
1.16%32.236.6%$43.62m
ICLRICON plc
0.93%162.904.2%$42.90m
ENDPEndo International Plc
0.42%4.848.8%$34.41m
UTHRUnited Therapeutics Corp.
1.53%91.6114.3%$33.37m
MYOKMyoKardia, Inc.
0.46%67.432.1%$30.25m

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. It's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The firm develops RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, United Kingdom.